Lamb Weston Gains 11.85% on Strong Results, Constellation Jumps 14.79% on Google Nuclear Deal, Option Care Surges 32.8% on $5.8B Takeover

Mumbai, 6 October 2026: Several companies saw notable stock moves on Tuesday following major corporate developments. Lamb Weston shares surged after strong earnings and higher guidance, while Option Care jumped on a $5.8 billion take-private deal. Apogee and Constellation rallied on better results and a major Google nuclear agreement, respectively. Meanwhile, Spyre and XCF declined on financing and transaction concerns. Boeing, Uber, Energy Transfer and International Bancshares also moved as investors assessed major contracts, acquisitions and strategic changes.

Lamb Weston Shares Jump 11.85% as Strong Q1 Results Lift 2027 Outlook

Lamb Weston Holdings (NYSE: LW) shares surged on Tuesday after the frozen potato products maker reported fiscal first-quarter results above expectations and raised its full-year 2027 financial outlook.

The stock was trading at $49.83, up 11.85%, at 12:26 p.m. EDT on October 6, while the U.S. market remained open. Shares opened at $47.03, compared with the previous close of $44.57. The stock has so far moved between a day high of $50.06 and a low of $46.78, reflecting a strong positive response to the results.

Lamb Weston reported first-quarter net sales of $1.67 billion, up 1% from $1.66 billion a year earlier. Adjusted net income was $103 million, unchanged year over year, while adjusted EBITDA declined 5% to $286 million. Adjusted diluted earnings per share rose slightly to $0.75 from $0.74.

North America remained the key growth driver. Segment sales increased 5% to $1.14 billion, supported by a 7% increase in sales volume and higher demand from existing customers and new customer wins. North American adjusted EBITDA rose 11% to $287 million.

International operations remained a weak spot, with sales falling 8% to $529 million and adjusted EBITDA plunging 54% to $27 million, largely because of weaker European performance and higher manufacturing costs.

For fiscal 2027, Lamb Weston raised its adjusted EBITDA outlook to $1.125 billion-$1.215 billion, from $1.10 billion-$1.20 billion previously. Adjusted diluted EPS guidance was also increased to $3.05-$3.35 from $2.95-$3.25.

The company said stronger North American volumes, cost savings and capacity optimization helped offset inflation, freight costs and lower price/mix.

Option Care Shares Rise 32.8% as McKesson, CD&R Agree $5.8B Take-Private Deal

Option Care Health (NASDAQ: OPCH) shares jumped on Tuesday after McKesson and private equity firm Clayton, Dubilier & Rice (CD&R) agreed to take the infusion therapy provider private in a deal valued at about $5.8 billion, including debt.

Option Care shares were trading at $31.08, up about 32.8%, at 12:37 p.m. EDT on October 6, while the U.S. stock market remained open. The shares opened at $31.04, compared with the previous close of about $23.40. The stock touched a day high of $31.09 and a low of $30.96 so far, moving close to the proposed offer price.

Under the agreement, shareholders will receive $32.05 per share in cash, representing a 37.1% premium to Option Care’s previous closing price. The transaction is expected to close in the first half of 2027, after which Option Care will become privately held.

McKesson will invest approximately $1.4 billion for a 49% stake in Option Care, while CD&R will hold the remaining 51%. McKesson will have the right to acquire CD&R’s stake in the future. Option Care will continue operating as a separate company under its existing management team.

Option Care is the largest independent infusion therapy provider in the U.S., serving more than 308,000 patients annually across more than 197 locations. Its services include home and ambulatory infusions, specialty pharmacy and treatment for complex conditions.

The deal comes as demand for home-based healthcare grows, with patients increasingly receiving treatment outside hospitals. Analysts said the transaction could strengthen McKesson’s healthcare-services footprint and benefit from the shift toward lower-cost, community-based care.

McKesson’s oncology and multispecialty segment, which includes infusion services, generated $14.2 billion in revenue in its latest quarter, up 33% year over year.

Also Read: How to invest in US stocks  

Apogee Shares Jump 18.7% as Earnings Beat and Guidance Lift Investor Sentiment

Apogee Enterprises (NASDAQ: APOG) shares surged on Tuesday after the architectural products provider reported second-quarter results well above analyst expectations and raised its full-year fiscal 2027 guidance.

The stock was trading at $42.33, up 18.70%, at 12:41 p.m. EDT on October 6, while the U.S. market remained open. Shares opened at $42.74 and have so far touched a day high of $42.74 and a low of $37.84. The stock’s previous closing price was approximately $35.67, putting it well above the prior session’s level.

Apogee reported adjusted earnings per share of $1.17 for the second quarter, significantly ahead of the analyst consensus of $0.63. Revenue rose 9.2% year over year to $391.1 million, exceeding expectations of $359.46 million.

The stronger performance was supported by disciplined pricing, productivity initiatives and a $16.4 million contribution from the Kalwall acquisition, although lower volumes amid mixed demand partly offset the gains.

The company raised its fiscal 2027 adjusted EPS outlook to $3.00-$3.40, from $2.70-$3.25 previously. Its revenue guidance was also increased to $1.46 billion-$1.50 billion, compared with the earlier range of $1.38 billion-$1.43 billion.

Apogee’s operating margin expanded 110 basis points to 8.6%, while adjusted EBITDA increased 11.7% to $49.5 million. Gross margin also improved to 24.6%.

The company recently completed acquisitions of Kalwall and Groglass, strengthening its product portfolio and exposure to targeted end markets.

Constellation Shares Jump 14.79% as Google Nuclear Deal Boosts Growth Outlook

Constellation Energy shares jumped 14.79% to $307.41 at 1:05 p.m. EDT Tuesday after the company announced a 20-year power purchase agreement with Google to expand nuclear power capacity in the PJM grid.

The stock opened at $291.11 and reached an intraday high of $309.80. It touched a low of $291.00. Based on the reported gain, Constellation closed at about $267.81 in the previous session.

Under the agreement, Constellation will add 890 megawatts of nuclear capacity through upgrades at 11 company-owned units across Illinois, Pennsylvania, and New Jersey. The company plans to invest more than $4.3 billion in new equipment and technology to improve thermal and electrical efficiency.

The project will support around 4,400 existing jobs and create about 7,200 construction jobs during the building phase. Constellation expects to deliver the first uprate by 2028.

The companies also signed a 15-year energy supply agreement covering another 2,700 megawatts from Constellation’s PJM nuclear fleet. This arrangement will help maintain reliable power supplies as electricity demand grows.

Constellation also expanded its technology partnership with Google by adopting Google Cloud and Gemini Enterprise. The companies aim to develop an AI-focused energy framework to improve capacity delivery, asset dispatch, and infrastructure protection.

The deal strengthens Constellation’s long-term growth prospects by combining nuclear capacity expansion with rising demand from technology and artificial intelligence infrastructure.

RPM Shares Rise 2.5% as Record Sales and Profit Boost Fiscal Outlook

RPM International (NYSE: RPM) shares moved higher on Tuesday after the specialty coatings and building materials maker reported record fiscal 2027 first-quarter results and maintained a positive outlook for the year.

The stock was trading at $96.89, up about 2.5%, at 12:49 p.m. EDT on October 6, while the U.S. market remained open. Shares opened at $96.25 and have traded between a day high of $98.75 and a low of $95.25. The previous closing price was approximately $94.52, putting the stock modestly above its prior-session level.

RPM reported record first-quarter sales of $2.22 billion, up 4.8% from $2.11 billion a year earlier. Net income attributable to RPM stockholders increased 12.6% to $256.4 million, while diluted earnings per share rose 13.6% to $2.01.

Adjusted results also reached records. Adjusted diluted EPS increased 5.3% to $1.98, while adjusted EBITDA rose 4.5% to $405.5 million. The company attributed the improvement to organic growth in its Performance Coatings and Consumer groups, alongside manufacturing, procurement and selling, general and administrative efficiencies.

Performance Coatings was the strongest segment, with sales rising 10.2% to $629.7 million and adjusted EBITDA climbing 18.2% to $121.1 million. Consumer Group sales increased 5.3% to $726.7 million, while adjusted EBITDA rose 5.5%.

Construction Products remained a drag. Sales increased just 0.8%, while adjusted EBITDA fell 9.7% amid weaker volumes, raw-material inflation, higher bad debt expense and warranty costs.

RPM expects fiscal 2027 second-quarter sales and adjusted EBITDA to grow in the low- to mid-single-digit range. For the full year, the company expects both metrics to increase in the mid-single-digit range.

Also Read: US Stock market timings  

Uber Shares Slip 0.71% as $2.3B ezCater Deal Expands Business Delivery

Uber Technologies shares fell 0.71% to $68.98 at 1:02 p.m. EDT on Tuesday as investors assessed the company’s $2.3 billion acquisition of workplace catering platform ezCater.

The stock opened at $69.56 and reached an intraday high of $69.94 before falling to a low of $68.90. Uber closed at about $69.47 in the previous session, based on Tuesday’s reported decline.

Uber agreed to acquire Boston-based ezCater in an all-cash transaction. The deal will combine ezCater’s workplace catering operations with Uber Eats and Uber for Business. The acquisition will expand Uber’s exposure to scheduled, higher-value business deliveries.

ezCater generated more than $2.5 billion in gross bookings over the trailing 12 months, with growth in the high teens. Its average order value exceeds $400. The platform connects businesses with more than 140,000 restaurants and provides tools to manage food orders and spending.

Uber expects the acquisition to add profitable operations and become margin accretive. Restaurants could also receive larger orders, while Uber Eats couriers could gain additional catering delivery opportunities.

Separately, Uber Freight appointed Erin Mitchell as senior vice president of implementation. Mitchell will lead customer onboarding for its Transportation Management business. Her experience at YMX Logistics and Kraft Heinz strengthens Uber Freight’s supply chain leadership.

The ezCater transaction remains subject to regulatory approvals and other closing conditions.

Energy Transfer Shares Fall 1.2% as $2.63B Vaquero Deal Expands Pipeline Network

Energy Transfer shares fell 1.2% to $20.52 at 1:07 p.m. EDT Tuesday after the company agreed to acquire Vaquero Midstream for about $2.63 billion in cash and stock.

The stock opened at $20.70 and reached a high of $20.74 before slipping to an intraday low of $20.34. Based on the reported decline, Energy Transfer closed at about $20.77 in the previous session.

The transaction includes $1.95 billion in cash and approximately 33.3 million newly issued Energy Transfer shares. The company expects the acquisition to strengthen its midstream operations and increase volumes across its existing natural gas and natural gas liquids infrastructure.

Vaquero operates roughly 300 miles of pipelines across Loving, Reeves, Ward and Winkler counties in Texas. Its assets serve producers in the Southern Delaware Basin and include the Caymus Processing Complex, which has three processing trains with combined capacity of about 675 million cubic feet per day.

Vaquero also has fee-based contracts backed by about 100,000 dedicated acres. The contracts carry an average remaining term of roughly 10 years, providing Energy Transfer with relatively predictable revenue.

The assets could add volumes to Energy Transfer’s transportation, fractionation, terminal and export businesses. The company expects the acquisition to close in the fourth quarter.

Despite the strategic expansion, shares declined during Tuesday’s session as investors assessed the transaction’s cost and stock issuance.

Skydance Shares Fall 4.71% as $70B Warner Bros. Deal Targets $6B Synergies

Skydance Corporation shares fell 4.71% to $9.32 at 1:09 p.m. EDT Tuesday after the company completed its acquisition of Warner Bros. Discovery, creating a major global entertainment company.

The newly listed SKYD shares opened at $9.84 and reached a high of $9.84 before falling to an intraday low of $9.12. The stock’s previous close stood at $9.77. Warner Bros. Discovery shares, meanwhile, stopped trading on Nasdaq after the transaction closed.

The combined company will operate as Skydance and bring together Paramount’s and WBD’s film studios, streaming platforms, television networks, news operations and sports assets. Its portfolio includes CBS, HBO, CNN, CBS Sports, TNT Sports and franchises such as Top Gun, Harry Potter and SpongeBob SquarePants.

Skydance expects the combination to generate at least $6 billion in run-rate synergies within three years. The company plans to reduce costs through technology integration, procurement, marketing and real estate savings.

The company will also target more than $10 billion in free cash flow by 2030 while reducing net leverage toward 3.0x by the end of 2029. Skydance expects to deliver at least 30 theatrical films annually and already has more than 180 television shows.

The deal received regulatory approval across nearly 70 jurisdictions. Skydance said its larger content library, streaming scale and technology capabilities will support growth and strengthen its position in global entertainment.

XCF Shares Fall 3.43% as Merger Approval Advances Renewable Fuel Expansion

XCF Global shares fell 3.43% to $0.29 at 1:11 p.m. EDT Tuesday after stockholders approved proposals needed to complete the company’s business combination with DevvStream and Southern Energy Renewables.

The stock opened at $0.30 and reached an intraday high of $0.32 before dropping to a low of $0.29. XCF closed at $0.30 in the previous session.

The approved proposals cover the issuance of XCF common stock as part of the planned transaction. The combination aims to expand XCF’s renewable fuel platform by adding Southern Energy’s fuel production technology and DevvStream’s environmental attribute monetization capabilities.

XCF operates a renewable diesel and sustainable aviation fuel business. Its flagship Reno facility has permitted nameplate production capacity of up to 38 million gallons annually.

The company previously raised $1 million through the sale of warrants exercisable at $2.50 per share. Management said the shareholder vote marks an important milestone and signals support for the strategic combination.

However, the transaction still faces remaining closing conditions. XCF warned that there is no guarantee the deal will close on the expected timeline.

The company also highlighted ongoing disputes involving its New Rise subsidiary, including a ground-lease disagreement with its Reno facility landlord and disputes with its primary lender over loans used to develop the facility.

Despite the shareholder approval, the stock declined during Tuesday’s session as investors weighed the transaction’s potential benefits against execution and financing risks.

Also Read: US Stock Market Timings 

Lycia Files IPO as Phase I Data Shows 96% IgE Reduction in Allergy Drug

Lycia Therapeutics filed an amended draft registration statement with the SEC on Tuesday for a proposed initial public offering, advancing plans to bring its protein-degrading technology to public markets.

The South San Francisco-based biotech did not disclose IPO pricing, share size, exchange or a proposed ticker symbol. Lycia’s LYTAC platform targets disease-causing proteins outside cells. Its cataLYTAC technology aims to repeatedly remove multiple copies of harmful proteins with a single degrader molecule.

The company’s lead candidate, LCA-0061, targets immunoglobulin E (IgE) and is being developed for food allergies and other allergic diseases. In the first Phase I cohort involving healthy atopic participants, a 70 mg subcutaneous dose produced a mean maximum IgE reduction of 96%. Most participants maintained reductions above 95% through day 28. Lycia reported no safety signals or dose-limiting toxicities in the cohort.

However, the early biomarker results do not yet demonstrate clinical benefit. Lycia is also advancing LCA-0062, another IgE-targeting degrader, through IND-enabling studies. Its LCA-0321 program is in Phase I testing for Graves’ disease.

The IPO proceeds would support these programs, pipeline research and general corporate purposes. Lycia held $148.1 million in cash entering the second half of 2026.

The company raised $75 million in a Series D financing in June and previously secured $106.6 million through a Series C round in 2024. It also maintains a collaboration with Eli Lilly covering up to five protein degraders for immunology and pain, with potential milestone payments exceeding $1.6 billion.

Spyre Shares Fall 13.54% as $350M Stock Offering Raises Dilution Concerns

Spyre Therapeutics shares fell 13.54% to $80.20 at 1:13 p.m. EDT Tuesday after the biotechnology company priced a $350 million underwritten stock offering at $85 per share.

The stock opened at $92.08 and reached a high of $92.08 before dropping to an intraday low of $79.36. Spyre closed at about $92.78 in the previous session, based on the reported decline.

The offering covers 4,117,648 common shares at $85 each. Spyre expects to receive about $350 million in gross proceeds before underwriting discounts, commissions and other expenses. Underwriters also have a 30-day option to purchase additional shares worth up to $52.5 million.

The offering is expected to close around October 7, subject to customary conditions. Spyre plans to use the proceeds to advance its immunology pipeline across gastroenterology, rheumatology and dermatology. The funding will support preclinical research, clinical trials, manufacturing activities and preparation for Phase 3 programs.

The company also plans to advance SPY072 into late-stage development for hidradenitis suppurativa. Remaining funds will support research and development, working capital and general corporate needs.

Spyre develops extended half-life antibodies targeting inflammatory pathways including α4β7, TL1A, IL-23 and IL-17A/F.

The sharp share-price decline reflects investor concerns about equity dilution from the new shares, despite the substantial funding that strengthens Spyre’s balance sheet and supports its clinical development programs.

Boost Run Shares Jump 9.98% as $525.6M AI Cloud Deal Expands Revenue

Boost Run shares jumped 9.98% to $15.68 at 1:22 p.m. EDT on Tuesday after the company signed a $525.6 million AI cloud services agreement. The stock opened at $15.60 and reached an intraday high of $16.25. It touched a low of $14.79.

The five-year contract with a sovereign AI company covers AI computing capacity powered by NVIDIA GB300 NVL72 GPUs. It also includes network storage and CPU node services. Boost Run expects the customer to begin accepting the initial infrastructure in early second-quarter 2027.

The agreement lifts Boost Run’s total contracted value above $2.6 billion. The figure represents revenue customers have committed to pay over the lifetime of its agreements, including upfront payments.

Chief Executive Officer Andrew Karos said the deal marks an important step in converting the company’s financing into contracted revenue.

Boost Run operates as an NVIDIA Preferred Cloud Partner and provides GPU computing, CPU nodes, managed Kubernetes orchestration and shared storage. Its platform supports these services through a management console and API layer.

The latest contract strengthens Boost Run’s revenue visibility and supports its strategy of deploying infrastructure against committed customer demand. It also gives the company another major contract as demand for AI computing capacity continues to expand.

Boost Run said it plans to keep converting its pipeline into signed agreements and deploy capacity against contracted demand, potentially supporting further growth in its AI cloud business.

BDX Shares Rise 0.3% as $19B U.S. Deal Strengthens Supply Resilience

Becton, Dickinson and Company shares rose about 0.3% to $181.25 at 1:12 p.m. EDT Tuesday after the medical technology company announced a major partnership with the U.S. government to expand domestic manufacturing. The stock was up about 0.32% from Monday’s $180.67 close.

BDX opened at $183.35 and reached an intraday high of $187.45 before falling to a low of $180.68. The stock remained close to Monday’s closing level despite the announcement.

Under the agreement, BD plans to invest $19 billion in the United States over several years across capital, operations and supply chains. About $3 billion will fund manufacturing expansion at strategic production sites.

The company also plans to increase domestic production by about 5 billion essential medical consumables annually. That investment would raise BD’s share of domestically supplied essential consumables to roughly 80%.

BD will also manufacture 100% of the needles it sells in the United States domestically using American-made steel.

The agreement provides relief from future Section 232 tariffs on covered BD products and inputs, subject to final rules and agreed milestones. BD said it cannot yet quantify the financial impact because tariff rates and product coverage remain undecided.

The partnership strengthens BD’s U.S. manufacturing footprint while improving supply-chain certainty. It also supports the company’s strategy to expand production of medical products used across roughly 90% of U.S. hospital visits.

Also Read: What Are Fractional Shares? 

Boeing Shares Fall 1.02% as $14.7B PAC-3 Contract Boosts Defense Demand

Boeing shares fell 1.02% to $190.78 at 1:17 p.m. EDT on Tuesday, despite the company securing a major defense contract from Lockheed Martin. The stock opened at $193.00 after closing at about $192.75 in the previous session. It traded between an intraday high of $193.22 and a low of $189.45.

Lockheed Martin awarded Boeing a seven-year contract valued at $14.7 billion to scale production of seekers for the Patriot Advanced Capability-3 Missile Segment Enhancement (PAC-3 MSE). Boeing said the agreement will allow it to triple seeker output and support growing global demand for missile defence systems.

The PAC-3 MSE interceptor can counter advanced threats, including ballistic and cruise missiles, hypersonic weapons and hostile aircraft. The contract also supports the U.S. Department of Defence’s efforts to strengthen the domestic defence industrial base.

Boeing has already invested more than $200 million since 2024 to expand its Huntsville, Alabama, manufacturing operations. The investment includes a 35,000-square-foot facility expansion, workforce development and domestic supply-chain improvements.

The latest award adds to Boeing’s recent defence momentum. The U.S. Navy recently selected the company for the F/A-XX sixth-generation fighter program, valued at more than $20 billion.

Together, the contracts could strengthen Boeing’s defence backlog and manufacturing scale, although the PAC-3 agreement still has some terms to finalise.

Informa Shares Rise 4% as £2.24B Clarion Deal Sharpens Growth Focus

Informa shares rose about 4% on Tuesday as investors responded to the company’s £2.24 billion ($3 billion) agreement to acquire events organiser Clarion from Blackstone.

The stock traded at 906.60 pence at 4:49 p.m. BST, after opening at 848.00 pence. It reached an intraday high of 918.60 pence and a low of 842.80 pence.

Informa will raise £940 million through a new equity issue to partly fund the acquisition. Clarion operates more than 100 business-to-business live event brands. The deal expands Informa’s events portfolio and strengthens its focus on the faster-growing B2B events market.

The company also started a formal process to separate its Taylor & Francis academic publishing business. Informa said it will review all options and provide an update with its full-year results in March 2027.

Taylor & Francis generated about 17% of Informa’s revenue in 2025 and has grown at roughly 4% annually. Management said both businesses could perform better as standalone operations.

The transactions would simplify Informa’s portfolio while increasing its exposure to live events. Analysts at JPMorgan said the moves could create a more focused B2B platform with stronger growth characteristics.

The Clarion acquisition marks one of Informa’s largest deals in recent years. It follows the company’s £3.8 billion acquisition of UBM in 2018.

For Blackstone, the sale provides an exit from Clarion as demand for live events continues to attract investors.

International Bancshares Shares Fall 0.34% as Listing Moves to Texas Exchange

International Bancshares shares fell 0.34% to $69.26 at 1:24 p.m. EDT on Tuesday after the bank holding company announced plans to move its primary stock listing from Nasdaq to the Texas Stock Exchange (TXSE).

The stock opened at $69.77 and traded between an intraday high of $69.97 and a low of $69.22. Based on the reported 0.34% decline, the previous close stood at about $69.50.

International Bancshares said its common stock will begin trading on TXSE on October 19 under the existing ticker, IBOC. The shares will continue trading on Nasdaq through the market close on October 16. The company said shareholders do not need to take any action for the transfer.

The Laredo, Texas-based bank operates five subsidiary banks across Texas and Oklahoma. Its network covers 75 communities through 165 facilities, while consolidated assets stand at about $17 billion.

Chairman and CEO Dennis E. Nixon said the move reflects the company’s long-standing connection to Texas, where its business has operated for 60 years. International Bancshares’ flagship bank began in Laredo in 1966 with less than $1 million in assets.

The listing change strengthens the company’s Texas-focused identity while keeping its ticker unchanged. Management also plans a closing-bell ceremony in Houston on December 7 to mark the transition.

Overall, Tuesday’s company-specific developments highlighted how earnings, acquisitions, major contracts, financing and strategic decisions continued to drive individual stock performance. Strong results and improved outlooks supported gains for companies such as Lamb Weston and Apogee, while major deals boosted Option Care and Constellation. In contrast, equity offerings and transaction-related concerns pressured shares of Spyre and XCF. Investors will continue watching execution, financial impact, regulatory approvals and management guidance as these developments shape future growth and valuations.